C12Y 207/10001
Receptor protein-tyrosine kinase
Official title: Receptor protein-tyrosine kinase (2.7.10.1)
C12Y207/10001 (Receptor protein-tyrosine kinase) appears on 195 US grants and 388 published applications in this corpus.
Search patents in C12Y- Granted patents
- 195
- Published applications
- 388
- Assignees
- 227
- Inventors
- 747
- Latest grant
- 11 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2004 | 0 | 1 |
| 2005 | 0 | 5 |
| 2006 | 0 | 1 |
| 2007 | 1 | 1 |
| 2008 | 2 | 4 |
| 2009 | 1 | 5 |
| 2010 | 1 | 8 |
| 2011 | 5 | 6 |
| 2012 | 4 | 9 |
| 2013 | 4 | 7 |
| 2014 | 4 | 13 |
| 2015 | 9 | 31 |
| 2016 | 14 | 42 |
| 2017 | 19 | 30 |
| 2018 | 14 | 33 |
| 2019 | 17 | 19 |
| 2020 | 19 | 20 |
| 2021 | 19 | 22 |
| 2022 | 11 | 38 |
| 2023 | 9 | 26 |
| 2024 | 16 | 23 |
| 2025 | 17 | 30 |
| 2026 | 9 | 14 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- NGF antagonists for medical use11 Aug 2026US 12,703,753 B2Elanco US Inc.
- Treatment of ocular neovascularization using anti-vegf proteins26 May 2026US 12,636,348 B2Avalanche Australia Pty Ltd.
- Compositions and methods of muscle specific kinase chimeric autoantibody receptor cells26 May 2026US 12,637,501 B2The Trustees of the University of Pennsylvania
- Compounds with anti-tumor activity against cancer cells bearing HER2 exon 21 insertions19 May 2026US 12,629,375 B2Board of Regents, The University of Texas System
- Anti-tumor composition12 May 2026US 12,622,936 B2Genemedicine Co., Ltd.
- Multi-target drug conjugate and use thereof for cancer treatment1 Oct 2026US 2026/0295061 A1Virginia Tech Intellectual Properties, Inc.
- Optogenetic activation for signal transduction17 Sep 2026US 2026/0274903 A1The Chinese University of Hong Kong
- Antibodies and uses thereof27 Aug 2026US 2026/0250421 A1Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
- Treatment of fragile x syndrome6 Aug 2026US 2026/0226116 A1UTI Limited Partnership
- Her receptor derived peptides and methods of use thereof16 Jul 2026US 2026/0200982 A1Ramot at Tel-Aviv University Ltd.
Most cited
By later US patents
- Truncated epiderimal growth factor receptor (EGFRt) for transduced T cell selection117US 8,802,374 B2City of Hope · 2014
- Inhibition of Syk kinase expression50US 7,173,015 B2The Trustees of the University of Pennsylvania · 2007
- Delivery of siRNA by neutral lipid compositions22US 8,895,717 B2Board of Regents, The University of Texas System · 2014
- Lipid vesicle compositions and methods of use21US 9,445,994 B2Massachusetts Institute of Technology · 2016
- Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate21US 9,782,414 B2Array BioPharma Inc. · 2017